Prosecution Insights
Last updated: October 25, 2026
Application No. 18/686,970

EPISULFIDE COMPOSITION, POLYMERIZABLE COMPOSITION, CURED PRODUCT, AND OPTICAL MATERIAL

Non-Final OA §102
Filed
Feb 27, 2024
Priority
Sep 01, 2021 — JP 2021-142430 +1 more
Examiner
NGUYEN, HA S
Art Unit
1766
Tech Center
1700 — Chemical & Materials Engineering
Assignee
Mitsui Chemicals Inc.
OA Round
1 (Non-Final)
58%
Grant Probability
Moderate
1-2
OA Rounds
6m
Est. Remaining
38%
With Interview

Examiner Intelligence

Grants 58% of resolved cases
58%
Career Allowance Rate
370 granted / 632 resolved
-6.5% vs TC avg
Minimal -21% lift
Without
With
+-20.7%
Interview Lift
resolved cases with interview
Typical timeline
3y 2m
Avg Prosecution
45 currently pending
Career history
680
Total Applications
across all art units

Statute-Specific Performance

§101
1.1%
-38.9% vs TC avg
§103
42.6%
+2.6% vs TC avg
§102
21.7%
-18.3% vs TC avg
§112
22.1%
-17.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 632 resolved cases

Office Action

§102
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1-10, is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by WO 2017/159839 A1 in which US 2019/0077751 A1 to Tokunaga is used as a US equivalent. (hereinafter Tokunaga). Regarding claims 1-10, Tokunaga teaches an episulfide compound having the formula PNG media_image1.png 67 185 media_image1.png Greyscale , wherein p is 0-4 (para 35) used in a polymerizable composition with a polythiol (para 113) and used in an optical material (para 113-114), which meets the composition of claims 7-10. In example 6, the episulfide compound is obtained from a reaction liquid containing 92.1 area% 1,8-dichloro-2,7-dihydroxy-4,5-dithiaoctane (compound B) and 4.5 area% 1,9-dichloro-2,8-dihydroxy-4,5,6-trithianonane (compound C), (See Table 1, para 135-139), which under goes an epoxidation reaction with a base to form an epoxy, (para 137-139), and then a sulfurizing reaction to form episulfide compounds (para 139-141), wherein the final product is 97.7 wt% bis(2,3-epithiopropyl)disulfide, (para 141), which meets the claimed episulfide compound (B). The above product would also result in some bis(2,3-epithiopropyl)trisulfide, which meets the claimed episulfide compound (A), as shown by the above epoxidation and sulfurizing reaction of 1,9-dichloro-2,8-dihydroxy-4,5,6-trithianonane (i.e. precursor of bis(2,3-epithiopropyl)trisulfide), as shown by the Applicant’s method of making in Example 1. Regarding the claimed content amounts, one skilled in the art would have a reasonable expectation for the above epoxidation and sulfurization reaction to the mixture of 92.1 are% 1,8-dichloro-2,7-dhydroxy-4,5-dithiaoctane and 4.5 are% 1,9-dichloro-2,8-dihydroxy-4,5,6-trithianonane of Tokunaga’1 to have the claimed content amounts in the episulfide composition of bis(2,3-epithiopropyl)disulfide (i.e. claimed compound B) and bis(2,3-epithiopropyl)trisulfide (i.e. claimed compound A) because Tokunaga teaches a substantially identical method as shown by the Applicant in Example 1 (See Example 1 of specification), such as an epoxidation reaction followed by a sulfurization reaction of a mixture of 1,8-dichloro-2,7-dhydroxy-4,5-dithiaoctane (i.e. the precursor of bis(2,3-epithiopropyl)disulfide) and 1,9-dichloro-2,8-dihydroxy-4,5,6-trithianonane (the precursor of bis(2,3-epithiopropyltrisulfide). See MPEP 2112.01. (Where the claimed and prior art products are identical or substantially identical in structure or composition, or are produced by identical or substantially identical processes, a prima facie case of either anticipation or obviousness has been established. In re Best, 562 F.2d 1252, 1255, 195 USPQ 430, 433 (CCPA 1977)). Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to HA S NGUYEN whose telephone number is (571)270-7395. The examiner can normally be reached Mon-Fri, Flex schedule 7:30am-4:00pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Randy Gulakowski can be reached at (571)272-1302. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /HA S NGUYEN/Primary Examiner, Art Unit 1766
Read full office action

Prosecution Timeline

Feb 27, 2024
Application Filed
Sep 30, 2026
Non-Final Rejection mailed — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12767868
TWO-PACK TYPE CURABLE ADHESIVE COMPOSITION
2y 9m to grant Granted Oct 20, 2026
Patent 12760147
TRANSITION METAL COMPLEX CATALYST COMPOSITION FOR POLYMERIZATION OF MONOMER HAVING CYCLIC ESTER GROUP AND METHOD OF PRODUCING POLYMER USING THE SAME
3y 2m to grant Granted Oct 13, 2026
Patent 12760140
MATRIX RESIN FOR PRODUCTION OF FIBRE COMPOSITE MATERIALS
3y 4m to grant Granted Oct 13, 2026
Patent 12753276
POLYESTER COPOLYMER HAVING EXCELLENT STRENGTH, AND PRODUCT COMPRISING THE SAME
3y 5m to grant Granted Oct 06, 2026
Patent 12753264
METHOD FOR PRODUCING BLOCK COPOLYMER
3y 5m to grant Granted Oct 06, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
58%
Grant Probability
38%
With Interview (-20.7%)
3y 2m (~6m remaining)
Median Time to Grant
Low
PTA Risk
Based on 632 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month